Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.

被引：0
|
作者：
Cazzaniga, Marina Elena
Pronzato, Paolo
Schettini, Francesco
Del Mastro, Lucia
Riemma, Maria
Alu, Massimiliano
Turletti, Anna
Giordano, Monica
Pugliese, Palma
De Angelis, Claudia
Garrone, Ornella
Marchetti, Paolo
Riccardi, Ferdinando
Bernardo, Antonio
Livi, Lorenzo
Fabi, Alessandra
Taverniti, Cristiana
De Placido, Sabino
Mustacchi, Giorgio
机构：
[1] ASST Monza, Phase Res Unit 1, Monza, Italy
[2] San Martino IST Ist Naz Ric Cancro, Genoa, Italy
[3] Univ Naples Federico II, Naples, Italy
[4] Natl Canc Inst, IRCCS AOU San Martino IST, Dept Med Oncol, Genoa, Italy
[5] Ist Nazl Tumori IRCCS, Fdn G Pascale, Breast Oncol Unit, Naples, Italy
[6] ARNAS Civ, Med Oncol Unit, Palermo, Italy
[7] ASLTO1 Osped Martini, Med Oncol, Turin, Italy
[8] Santa Anna Hosp, Como, Italy
[9] AOS Anna UO Oncol Med, Como, Italy
[10] Osped S Chiara, ITT, AOU Pisana, Med Oncol, Pisa, Italy
[11] S Croce & Carle Teaching Hosp, Breast Unit Med Oncol, Cuneo, Italy
[12] St Andrea Univ Hosp, Dept Med Oncol, Rome, Italy
[13] Cardarelli Hosp, Breast Unit, Naples, Italy
[14] Fdn Maugeri IRCCS, Pavia, Italy
[15] Univ Florence, Florence, Italy
[16] Regina Elena Inst Canc Res, Div Med Oncol, Rome, Italy
[17] AOU Citta Salute & Sci, Med Oncol, Turin, Italy
[18] Univ Federico II Naples, Dept Clin Med & Surg, Oncol Unit, Naples, Italy
[19] Univ Trieste, Trieste, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e12528
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12528
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study
    Cazzaniga, Marina Elena
    De Placido, Sabino
    D'Alonzo, Alessia
    Piezzo, Michela
    Natoli, Clara
    Milani, Andrea
    Bologna, Alessandra
    Alu, Massimiliano
    Turletti, Anna
    Pugliese, Palma
    Biganzoli, Laura
    De Angelis, Claudia
    Garrone, Ornella
    Marchetti, Paolo
    Riccardi, Ferdinando
    Bernardo, Antonio
    Livi, Lorenzo
    Fabi, Alessandra
    Taverniti, Cristiana
    Romagnoli, Emanuela
    Pronzato, Paolo
    Mustacchi, Giorgio
    CANCER RESEARCH, 2020, 80 (04)
  • [2] First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study.
    Pronzato, Paolo
    Mustacchi, Giorgio
    Giordano, Monica
    Garrone, Ornella
    Del Mastro, Lucia
    Natoli, Clara
    Turletti, Anna
    Romagnoli, Emanuela
    Bologna, Alessandra
    Mocerino, Carmela
    Alu, Massimiliano
    De Angelis, Claudia
    Aversa, Caterina
    Arpino, Grazia
    Taverniti, Cristiana
    Biganzoli, Laura
    Meattini, Icro
    Piezzo, Michela
    Cazzaniga, Marina Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly-Preliminary results of the GIM-13 AMBRA study.
    Mustacchi, Giorgio
    Pronzato, Paolo
    D'Alonzo, Alessia
    Mocerino, Carmela
    Romagnoli, Emanuela
    Garrone, Ornella
    Blasi, Livio
    De Laurentiis, Michelino
    Michelotti, Andrea
    Bologna, Alessandra
    Giordano, Monica
    Turletti, Anna
    Montemurro, Filippo
    De Placido, Sabino
    Natoli, Clara
    Taverniti, Cristiana
    Biganzoli, Laura
    Meattini, Icro
    Marchetti, Paolo
    Cazzaniga, Marina Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Choices of first-line therapy in her2-ve advanced breast cancer (abc) patients (pts). prelimary results of the gim-13-ambra study
    Cazzaniga, M. E.
    Mustacchi, G.
    Giordano, M.
    Garrone, O.
    Donadio, M.
    Del Mastro, L.
    Livi, L.
    Natoli, C.
    Michelotti, A.
    Turletti, A.
    Riccardi, F.
    Paolo, P.
    De Placido, S.
    De laurentiis, M.
    Marchetti, P.
    Montemurro, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] NAB-PACLITAXEL (NAB-P) IN HER2-VE ADVANCED BREAST CANCER (ABC) PATIENTS (PTS): FOCUS ON LUMINAL CANCERS. RESULTS FROM GIM13-AMBRA STUDY
    Cazzaniga, Marina Elena
    Mustacchi, Giorgio
    Bria, Emilio
    Bisagni, Giancarlo
    Biganzoli, Laura
    Pronzato, Paolo
    De Placido, Sabino
    Romagnoli, Emanuela
    Montemurro, Filippo
    Marchetti, Paolo
    De laurentis, Michelino
    Riccardi, Ferdinando
    Turletti, Anna
    Michelotti, Andrea
    Natoli, Clara
    Livi, Lorenzo
    Del Mastro, Lucia
    Donadio, Michela
    Garrone, Ornella
    Giordano, Monica
    BREAST, 2017, 36 : S51 - S52
  • [6] 2Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): focus on luminal cancers. Results from GIM13-AMBRA study
    Mustacchi, G.
    Cazzaniga, M.
    Giordano, M.
    Garrone, O.
    Donadio, M.
    Del Mastro, L.
    Livi, L.
    Natoli, C.
    Michelotti, A.
    Turletti, A.
    Riccardi, F.
    Marchetti, P.
    Montemurro, F.
    Romagnoli, E.
    De Placido, S.
    Biganzoli, L.
    Bisagni, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer
    Kiechle, M.
    Simstich, N. S.
    Schwarz-Boeger, U. R.
    Paepke, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.
    Mustacchi, Giorgio
    Cazzaniga, Marina Elena
    Romagnoli, Emanuela
    Montemurro, Filippo
    De laurentiis, Michele
    Riccardi, Ferdinando
    Turletti, Anna
    Beano, Alessandra
    De Angelis, Claudia
    Graziano, Vincenzo
    Livi, Lorenzo
    Del Mastro, Lucia
    Biganzoli, Laura
    Garrone, Ornella
    De Placido, Sabina
    Marchetti, Paolo
    Pronzato, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Fulvestrant (FUL) as first-line therapy in HR1ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study
    Pronzato, P.
    Mustacchi, G.
    Riccardi, F.
    Turletti, A.
    Michelotti, A.
    Natoli, C.
    Livi, L.
    Del Mastro, L.
    Donadio, M.
    Garrone, O.
    Giordano, M.
    De laurentiis, M.
    Marchetti, P.
    Montemurro, F.
    Romagnoli, E.
    De Placido, S.
    Biganzoli, L.
    Cazzaniga, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Validation of time to treatment change (TTC) as a surrogate end-point of progression free survival (PFS) for observational trials in metastatic breast cancer patients (MBC): The GIM-13 AMBRA study.
    Cazzaniga, Marina Elena
    Pronzato, Paolo
    Meattini, Icro
    Biganzoli, Laura
    Taverniti, Cristiana
    Natoli, Clara
    De Placido, Sabino
    Aversa, Caterina
    Bordin, Elio
    Giordano, Monica
    Bologna, Alessandra
    Diodati, Lucrezia
    Blasi, Livio
    Garrone, Ornella
    Romagnoli, Emanuela
    Mocerino, Carmela
    D'Alonzo, Alessia
    Piezzo, Michela
    Mustacchi, Giorgio
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345